- Home
- EMF vs ADAP Comparison
EMF vs ADAP Comparison
Compare EMF & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMF
- ADAP
- Stock Information
- Founded
- EMF 1987
- ADAP 2008
- Country
- EMF United States
- ADAP United Kingdom
- Employees
- EMF N/A
- ADAP N/A
- Industry
- EMF Finance/Investors Services
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- EMF Finance
- ADAP Health Care
- Exchange
- EMF Nasdaq
- ADAP Nasdaq
- Market Cap
- EMF 196.6M
- ADAP 158.6M
- IPO Year
- EMF N/A
- ADAP 2015
- Fundamental
- Price
- EMF $13.31
- ADAP $0.56
- Analyst Decision
- EMF
- ADAP Strong Buy
- Analyst Count
- EMF 0
- ADAP 4
- Target Price
- EMF N/A
- ADAP $2.79
- AVG Volume (30 Days)
- EMF 29.3K
- ADAP 623.5K
- Earning Date
- EMF 01-01-0001
- ADAP 03-05-2025
- Dividend Yield
- EMF 6.16%
- ADAP N/A
- EPS Growth
- EMF N/A
- ADAP N/A
- EPS
- EMF N/A
- ADAP N/A
- Revenue
- EMF N/A
- ADAP $175,041,000.00
- Revenue This Year
- EMF N/A
- ADAP $204.91
- Revenue Next Year
- EMF N/A
- ADAP N/A
- P/E Ratio
- EMF N/A
- ADAP N/A
- Revenue Growth
- EMF N/A
- ADAP 146.27
- 52 Week Low
- EMF $10.58
- ADAP $0.53
- 52 Week High
- EMF $12.67
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- EMF 80.57
- ADAP 40.12
- Support Level
- EMF $12.56
- ADAP $0.55
- Resistance Level
- EMF $13.22
- ADAP $0.61
- Average True Range (ATR)
- EMF 0.13
- ADAP 0.03
- MACD
- EMF 0.09
- ADAP -0.00
- Stochastic Oscillator
- EMF 94.80
- ADAP 12.14
About EMF Templeton Emerging Markets Fund
Templeton Emerging Markets Fund is a closed-end management investment company. It seeks long-term capital appreciation by investing, under normal market conditions, at least 80% of its net assets in emerging country equity securities. It invests in various sectors such as Pharmaceuticals, Beverages, Broadline Retail, Metals &Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, insurance, Entertainment, and others.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.